These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34226728)

  • 1. Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.
    Chen AY; Wolchok JD; Bass AR
    Nat Rev Rheumatol; 2021 Sep; 17(9):577-578. PubMed ID: 34226728
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.
    Montfort A; Virazels M; Colacios C; Meyer N; Ségui B
    Nat Rev Rheumatol; 2021 Sep; 17(9):577. PubMed ID: 34226729
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
    Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
    Front Immunol; 2020; 11():1075. PubMed ID: 32547560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to "Immune checkpoint inhibitor-related dermatologic adverse events".
    Stephan C; Khalil J; Abbas O
    J Am Acad Dermatol; 2021 Jun; 84(6):e297-e298. PubMed ID: 33662463
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply.
    Wang Z; Zhao Z; Wang J
    JAMA Oncol; 2020 Jul; 6(7):1116-1117. PubMed ID: 32352479
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.
    Bersanelli M; Scala S; Affanni P; Veronesi L; Colucci ME; Banna GL; Cortellini A; Liotta F
    Immunotherapy; 2020 Feb; 12(2):105-110. PubMed ID: 32046555
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy combinations for the treatment of patients with solid tumors.
    Bluthgen MV; Basté N; Recondo G
    Future Oncol; 2020 Aug; 16(23):1715-1736. PubMed ID: 32501724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in cancer immunotherapy.
    Himmel ME; Saibil SD; Saltman AP
    CMAJ; 2020 Jun; 192(24):E651. PubMed ID: 32540906
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
    Gorbet MJ; Ranjan A
    Pharmacol Ther; 2020 Mar; 207():107456. PubMed ID: 31863820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
    Navani V; Graves MC; Bowden NA; Van Der Westhuizen A
    Br J Clin Pharmacol; 2020 Sep; 86(9):1736-1752. PubMed ID: 32384184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ["Immune checkpoint inhibitors in oncology"].
    Daëron M; Vivier É
    Rev Prat; 2021 Apr; 71(4):374-379. PubMed ID: 34161001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response.
    McGoverne I; Dunn J; Batham J; Tu WJ; Chrisp J; Rao S
    BMC Immunol; 2020 Apr; 21(1):22. PubMed ID: 32316916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
    Hussain N; Naeem M; Pinato DJ
    Hum Vaccin Immunother; 2021 Jan; 17(1):55-61. PubMed ID: 32574106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
    Kim HJ; Cantor H; Cosmopoulos K
    Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
    Qi Y; Liu B; Sun Q; Xiong X; Chen Q
    Front Immunol; 2020; 11():578877. PubMed ID: 33329549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.